LON:GNS

Genus Share Forecast, Price & News

GBX 4,883

-99.00 (-1.99 %)

(As of 06/24/2021 04:27 PM ET)

Add

Compare

Today's Range

4,876

▼

5,015

50-Day Range

4,694

▼

5,350

52-Week Range

3,289.44

▼

5,515

Volume36,814 shs

Average Volume97,792 shs

Market Capitalization£3.19 billion

P/E Ratio66.35

Dividend Yield0.60%

BetaN/A

30 days | 90 days | 365 days | Advanced Chart

Receive GNS News and Ratings via Email

Sign-up to receive the latest news and ratings for Genus and its competitors with MarketBeat's FREE daily newsletter.

About Genus

Genus plc operates as an animal genetics company in North America, Latin America, the United Kingdom, rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Research and Development. It sells sows, boars, and semen to breed pigs with various characteristics for pork production under the PIC brand. The company also sells bull semen and embryos to breed calves with various characteristics for milk and beef production under the ABS, Genus, and Bovec brands. In addition, it offers semen sexing, in vitro fertilization, reproductive, and other technical services to farmers. Genus plc has a strategic porcine collaboration with Beijing Capital Agribusiness Co. Ltd to research, develop, register, and market porcine reproductive and respiratory syndrome virus resistant pigs. The company was incorporated in 1994 and is based in Basingstoke, the United Kingdom.

Genus (LON:GNS) Receives "Buy" Rating from Liberum Capital
June 23, 2021 | americanbankingnews.com

Genus' (GNS) Buy Rating Reiterated at Peel Hunt
June 22, 2021 | americanbankingnews.com

Genus (LON:GNS) Receives "Buy" Rating from Peel Hunt
June 22, 2021 | americanbankingnews.com

Genus (LON:GNS) Stock Price Passes Above Two Hundred Day Moving Average of $0.00
June 16, 2021 | americanbankingnews.com

Genus (LON:GNS) Stock Passes Above Two Hundred Day Moving Average of $0.00
June 8, 2021 | americanbankingnews.com

Genus plc (LON:GNS) On An Uptrend: Could Fundamentals Be Driving The Stock?
June 2, 2021 | finance.yahoo.com

Genus plc Reports Interim First Half 2021 Fiscal Year Results
February 25, 2021 | finance.yahoo.com

Here's What Genus plc's (LON:GNS) Shareholder Ownership Structure Looks Like
February 22, 2021 | finance.yahoo.com

Genus plc Provides Update on Financial Performance for First Half of Fiscal 2021
January 19, 2021 | finance.yahoo.com

Genus plc's (LON:GNS) Financials Are Too Obscure To Link With Current Share Price Momentum: What's In Store For the Stock?
December 24, 2020 | finance.yahoo.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange LON
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolLON:GNS
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.genusplc.com
Phone+44-1256-347100
Employees3,100
Year FoundedN/A

Sales & Book Value

Annual Sales£566.40 million
Price / Sales5.63
Cash FlowGBX 74.21 per share
Price / Cash Flow65.80
Book ValueGBX 769.20 per share
Price / Book6.35

Profitability

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares65,308,000
Market Cap£3.19 billion
Next Earnings Date9/6/2021 (Estimated)
OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

1.54 out of 5 stars

2.5 Analyst's Opinion

Consensus Rating
Genus has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of GBX 5,543.33, Genus has a forecasted upside of 12.7% from its current price of GBX 4,918.
Amount of Analyst Coverage
Genus has only been the subject of 3 research reports in the past 90 days.

2.7 Community Rank

Outperform Votes
Genus has received 345 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Genus has received 286 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Genus has received 54.68% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Genus and other stocks. Vote “Outperform” if you believe GNS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe GNS will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.8 Dividend Strength

Dividend Yield
Genus has a dividend yield of 0.60%, which is in the bottom 25% of all stocks that pay dividends.
Dividend Growth
Genus does not have a long track record of dividend growth.
Dividend Coverage
The dividend payout ratio of Genus is 0.40%. This payout ratio is at a healthy, sustainable level, below 75%.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Genus insiders have bought more of their company's stock than they have sold. Specifically, they have bought £24,151.80 in company stock and sold GBX 0 in company stock.

0.0 Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Genus is 66.82, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 22.36.
Price to Earnings Ratio vs. Sector
The P/E ratio of Genus is 66.82, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 44.57.
Price to Book Value per Share Ratio
Genus has a P/B Ratio of 6.39. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Genus (LON:GNS) Frequently Asked Questions

Is Genus a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Genus in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Genus stock.
View analyst ratings for Genus or view top-rated stocks.

What stocks does MarketBeat like better than Genus?

Wall Street analysts have given Genus a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Genus wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Genus' next earnings date?

Genus is scheduled to release its next quarterly earnings announcement on Monday, September 6th 2021.
View our earnings forecast for Genus.

How has Genus' stock been impacted by Coronavirus?

Genus' stock was trading at GBX 3,472 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, GNS shares have increased by 40.6% and is now trading at GBX 4,883.
View which stocks have been most impacted by COVID-19.

How often does Genus pay dividends? What is the dividend yield for Genus?

Genus declared a dividend on Thursday, February 25th. Investors of record on Thursday, March 4th will be given a dividend of GBX 10.30 per share on Thursday, April 1st. This represents a yield of 2.06%. The ex-dividend date of this dividend is Thursday, March 4th. The official announcement can be seen at this link.
View Genus' dividend history.

Is Genus a good dividend stock?

Genus pays an annual dividend of GBX 0.29 per share and currently has a dividend yield of 0.60%. The dividend payout ratio of Genus is 0.40%. This payout ratio is at a healthy, sustainable level, below 75%.
View Genus' dividend history.

What price target have analysts set for GNS?

3 Wall Street analysts have issued 1 year price objectives for Genus' shares. Their forecasts range from GBX 5,500 to GBX 5,630. On average, they expect Genus' stock price to reach GBX 5,543.33 in the next year. This suggests a possible upside of 13.5% from the stock's current price.
View analysts' price targets for Genus or view top-rated stocks among Wall Street analysts.

Who are Genus' key executives?

Genus' management team includes the following people:

Mr. Stephen Wilson, CEO & Exec. Director (Age 61, Pay $1.57M)
Ms. Alison Henriksen, CFO & Exec. Director (Age 54, Pay $721.22k)
Dr. William Christianson, Chief Operating Officer
Dr. Elena Rice, Head of R&D and Chief Scientific Officer
Mr. Dan Hartley, Group Gen. Counsel & Company Sec.
Ms. Angelle R. Rosata, Group HR Director
Mr. Jerry Thompson, Chief Operating Officer of Genus ABS Beef
Dr. Nate Zwald, Chief Operating Officer of Genus ABS Dairy
Ms. Janet Duane, Group Financial Controller

Who are some of Genus' key competitors?

Some companies that are related to Genus include Cronos Group (CRON), BTG (BTG), Abcam (ABC), MorphoSys (MOR), Trillium Therapeutics (TRIL), Concordia International (CXR), Oxford Biomedica (OXB), PureTech Health (PRTC), Janux Therapeutics (JANX), Brooklyn ImmunoTherapeutics (BTX), Biotest Aktiengesellschaft (BIO), Ergomed (ERGO), Silence Therapeutics (SLN), Inventiva (IVA) and Theratechnologies (TH).
View all of GNS's competitors.

What other stocks do shareholders of Genus own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Genus investors own include Clinigen Group (CLIN), Glencore (GLEN), Tesco (TSCO), AstraZeneca (AZN), British American Tobacco (BATS), Cronos Group (CRON), Dairy Crest Group (DCG), Debenhams (DEB), Diageo (DGE) and Experian (EXPN).

What is Genus' stock symbol?

Genus trades on the London Stock Exchange (LON) under the ticker symbol "GNS."

How do I buy shares of Genus?

Shares of GNS and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Genus' stock price today?

One share of GNS stock can currently be purchased for approximately GBX 4,883.

How much money does Genus make?

Genus has a market capitalization of £3.19 billion and generates £566.40 million in revenue each year.

How many employees does Genus have?

Genus employs 3,100 workers across the globe.

What is Genus' official website?

The official website for Genus is www.genusplc.com.

Where are Genus' headquarters?

Genus is headquartered at Matrix House, Basing View, BASINGSTOKE, RG21 4DZ, United Kingdom.

How can I contact Genus?

Genus' mailing address is Matrix House, Basing View, BASINGSTOKE, RG21 4DZ, United Kingdom. The company can be reached via phone at +44-1256-347100.

This page was last updated on 6/24/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here